Cargando…

Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma

Background: Ameloblastoma is a rare head and neck tumor characterized by a high incidence of BRAF mutation providing a rationale for the use of BRAF inhibitors in patients with advanced disease. Methods: We report the case of a 26-year old female presenting with metastatic ameloblastoma. A molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunet, Maxime, Khalifa, Emmanuel, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861385/
https://www.ncbi.nlm.nih.gov/pubmed/31781502
http://dx.doi.org/10.3389/fonc.2019.01204